Dravet syndrome treatment accounted for a market value of US$ 288.2 Mn in 2021 and projected to grow at a CAGR of 11.7% during the forecast period from 2025 to 2033. The current treatment options available for Dravet syndrome target specifically the symptomatic relief associated with epileptic seizures. However, recent drug approvals for Dravet syndrome treatment has increased the overall market size and attracted attention of major pharmaceutical companies.
The learning disability treatment market is set to reach US$ 30,493.1 Mn by 2029 from US$ 17,418.0 Mn in 2020 highlighting steady growth at a compounded annual growth rate (CAGR) of 6.5% during the forecast period from 2021 to 2029. Children with learning disability have tremendous mental ability but due to irregular impulses generated by the central nervous system they suffer with altered behavior and lower cognitive skills. If diagnosed at an early stage with proper medical intervention will improve the quality of life of the patient suffering with learning disability.
The donor egg IVF treatment market is set to reach US$ 4,655.2 Mn by 2033 from US$ 2,081.4 Mn in 2020 highlighting moderate growth at a compounded annual growth rate (CAGR) of 8.4% during the forecast period from 2025 to 2033. In the last 2 decades there has been a paradigm shift observed in society which has major influence over the consistently growing infertility rate. Significant rise in working women, delayed marriages, advanced maternal age, etc provide a positive impetus for the donor egg IVF treatment market.
Virus filtration market accounted for a market value of US$ 2,764.1 Mn in 2020 and is projected to grow at a CAGR of 9.5% during the forecast period from 2025 to 2033. Virus filtration through membranes with pores.
The vitamin D therapy market is set to reach US$ 6329.5 Mn by 2033 from US$ 2572.8 Mn in 2021 showcasing spectacular growth at a compounded annual growth rate (CAGR) of 10.6% during the forecast period from 2025 to 2033. As per the research findings of International Osteoporosis Foundation (IOF), one in three women and one in five men above the age of 50 years is prone to suffer with fracture during their lifetime.
Modular robotic systems are self-configurable modular robots or self-configuring robotic units that can reconfigure themselves to adapt to the changing environment. These robots are capable of performing different functions or roles such as designing, controlling, fabricating and motion controlling on the basis of their different shapes. Modular robotics uses 3D patterned lattice architecture for assembling various components of the robot.
The life science instrumentation market is set to reach US$ 107,344.2 Mn by 2033 from US$ 68,336.6 Mn in 2021 showcasing moderate growth at a compounded annual growth rate (CAGR) of 6.5% during the forecast period from 2025 to 2033. Technological advancement in life science instruments and stringent healthcare norms pertaining to food and drug manufacturing processes drive market growth for life science instrumentation techniques.
The global GERD devices market is growing proficiently, expected to grow at a CAGR of 3.7%. GERD is a common disease with the highest prevalence in North America. A recent study from the U.S. revealed that prevalence of gastroesophageal reflux disease ranged from 18% to 27% in North America, 8% to 25% in Europe, 8% to 30% in the Middle East, 2% to 7% in Asia, and around 22% in Latin America.
The recombinant plasma protein therapeutics market is set to grow from US$ 8,435.3 Mn in 2021 to US$ 17,231.07 Mn in 2033 expanding at an annual growth rate of 8.3% during the forecast period from 2025 to 2033. According to World Federation of Hemophilia (WFH), approximately 1 in 1,000 people worldwide suffer with some form of bleeding disorder, 75% of them gain inadequate treatment and remain undiagnosed.
The stem cell alopecia treatment market is set to grow at a compounded annual growth rate (CAGR) of 5.1% during the forecast period from 2025 to 2033. According to the research findings of National Institute of Health (NIH), the global prevalence rate of androgenic alopecia is 15.33% and is highly variable according to geographical region.
The drugs by therapeutic area include therapy for oncology, cardiovascular, central nervous system, infectious diseases, respiratory, and others. The therapeutic area represents the specific area of medicine where the drug is intended to be used, based on its mechanism of action and intended clinical use. One of the primary drivers of the drugs by therapeutic area market is the increasing prevalence of diseases worldwide. Chronic diseases such as cancer, cardiovascular diseases, and neurological disorders are a significant burden on healthcare systems globally. There is an urgent need for new and effective therapies to treat these diseases, which has led to the growth of the drugs in the therapeutic area market.
The revenues generated by the drugs in the therapeutic area market have been consistently high over the years. The global pharmaceutical market is expected to reach USD 1.5 trillion by 2023, with oncology being the leading therapeutic area. The increasing demand for new therapies, coupled with advancements in technology and an increasing focus on personalized medicine, is expected to drive the growth of the market in the coming years. One of the emerging trends in the drugs by therapeutic area market is the increasing use of precision medicine. Precision medicine involves tailoring medical treatments to individual patients based on their unique genetic and molecular profiles. The development of precision medicine requires the use of advanced diagnostic tools and drug discovery technologies, which have contributed to the growth of drugs in the therapeutic area market.
Another trend in the drugs by therapeutic area market is the increasing focus on biologics. Biologics are drugs that are produced from living cells and are used to treat a wide range of diseases, including cancer and autoimmune disorders. Biologics are more complex than traditional small-molecule drugs, and their development requires specialized manufacturing processes and clinical trial design. The increasing demand for biologics has contributed to the growth of the drugs by therapeutic area market. The increasing focus on rare diseases is also driving the growth of the drugs by therapeutic area market. Rare diseases are defined as diseases that affect fewer than 200,000 people in the United States. Although each rare disease affects a small number of people, there are over 7,000 rare diseases, which together affect millions of people worldwide. There is an urgent need for new therapies to treat rare diseases, which has led to the growth of drugs in the therapeutic area market.
The increasing use of combination therapies is driving the growth of the drugs by therapeutic area market. Combination therapies involve the use of two or more drugs to treat a disease. Combination therapies can improve patient outcomes by targeting multiple pathways involved in the disease process. The development of combination therapies requires the use of advanced drug discovery technologies and clinical trial design, which has contributed to the growth of the drugs by therapeutic area market. The increasing prevalence of diseases worldwide, advancements in technology, and the emerging trends in precision medicine, biologics, rare diseases, and combination therapies are expected to drive the growth of the drugs by therapeutic area market.
